'Promising' Status For Faron's Traumakine In UK Opens Possibilities For Early Access, Pricing Negotiations
The UK regulator has granted a "promising designation" to Faron Pharmaceuticals' Traumakine acute respiratory distress syndrome treatment, which means the orphan drug may be made available to patients pre-approval under the early access scheme. The drug is currently in Phase III in the EU and Japan, with 420 moderate to severe ARDS patients expected to be treated.
You may also be interested in...
Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers.
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.